Special Shaperons exclusive technology to fuel global expansion - KBR
334970 Stock | KRW 5,100 100.00 1.92% |
About 61% of Prestige Biologics' investor base is looking to short. The analysis of current outlook of investing in Prestige Biologics Co suggests that many traders are alarmed regarding Prestige Biologics' prospects. The current market sentiment, together with Prestige Biologics' historical and current headlines, can help investors time the market. In addition, many technical investors use Prestige Biologics stock news signals to limit their universe of possible portfolio assets.
Prestige |
Special Shaperons exclusive technology to fuel global expansion KBR
Read at news.google.com
Prestige Biologics Fundamental Analysis
We analyze Prestige Biologics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Prestige Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Prestige Biologics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash And Equivalents
Cash And Equivalents Comparative Analysis
Prestige Biologics is number one stock in cash and equivalents category among its peers. Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Prestige Biologics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Prestige Biologics stock to make a market-neutral strategy. Peer analysis of Prestige Biologics could also be used in its relative valuation, which is a method of valuing Prestige Biologics by comparing valuation metrics with similar companies.
Peers
Prestige Biologics Related Equities
302440 | SK Bioscience | 8.65 | ||||
207940 | Samsung Biologics | 0.62 | ||||
144510 | Green Cross | 0.20 | ||||
235980 | MedPacto | 1.06 | ||||
334970 | Prestige Biologics | 1.92 | ||||
086890 | ISU Abxis | 2.92 | ||||
226950 | OliX PharmaceuticalsI | 3.11 |
Complementary Tools for Prestige Stock analysis
When running Prestige Biologics' price analysis, check to measure Prestige Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Prestige Biologics is operating at the current time. Most of Prestige Biologics' value examination focuses on studying past and present price action to predict the probability of Prestige Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Prestige Biologics' price. Additionally, you may evaluate how the addition of Prestige Biologics to your portfolios can decrease your overall portfolio volatility.
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume |